A randomized clinical trial of granulocyte macrophage colony stimulating factor mouthwash for oral mucositis in head and neck cancer

2022 ◽  
pp. 102093
Author(s):  
Marylin J. Dodd ◽  
Maria H. Cho ◽  
Bruce A. Cooper ◽  
Laurie MacPhail ◽  
Christine Miaskowski
Keyword(s):  
Clinical Trial ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Randomized Clinical Trial ◽  
Neck Cancer ◽  
Oral Mucositis ◽  
Colony Stimulating Factor ◽  
Macrophage Colony Stimulating Factor ◽  
Macrophage Colony ◽  
Stimulating Factor

Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy.

1995 ◽  
Vol 13 (10) ◽  
pp. 2620-2628 ◽  
Author(s):  
K H Chi ◽  
C H Chen ◽  
W K Chan ◽  
K C Chow ◽  
S Y Chen ◽  
...  
Keyword(s):  
Head And Neck ◽  
Oral Mucositis ◽  
Radiation Therapy Oncology Group ◽  
Period Effect ◽  
Colony Stimulating Factor ◽  
Gm Csf ◽  
Functional Scores ◽  
Macrophage Colony Stimulating Factor ◽  
Macrophage Colony ◽  
Stimulating Factor

PURPOSE To evaluate prospectively the efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) in the reduction of chemotherapy-induced oral mucositis. PATIENTS AND METHODS Twenty patients with stage IV squamous cell carcinoma of head and neck were studied. Two-cycles (periods) of identical doses of cisplatin, fluorouracil (5-FU), and leucovorin (PFL) chemotherapy with cisplatin 20 mg/m2/d, 5-FU 800 mg/m2/d, leucovorin 90 mg/m2/d by 96-hour continuous intravenous infusion every 3 weeks were given to each patient. After PFL chemotherapy, GM-CSF 4 micrograms/kg subcutaneously from days 5 to 14 or no therapy was given by a randomized self-controlled crossover study design. Oral mucositis was graded with modified Radiation Therapy Oncology Group criteria. RESULTS In the first cycle of PFL chemotherapy, GM-CSF significantly reduced the incidence, mean duration, and mean area under the curve (AUC) of severe oral gross mucositis (grade > or = 3) compared with no therapy. These beneficial effects continued into the second cycle of PFL chemotherapy after crossover to no GM-CSF. The incidence of severe mucositis was reduced when GM-CSF was given in the second cycle of PFL. Analysis of variance indicated significant direct GM-CSF treatment effects on the mean AUC of gross/functional scores and duration of moderate gross mucositis (grade > or = 2) over both periods. There was a significant period effect in favor of giving GM-CSF in the first cycle of chemotherapy. CONCLUSION GM-CSF can significantly reduce the severity and duration of chemotherapy-induced oral mucositis after PFL chemotherapy.

Die Stimulation von Vorläuferzellen des Gefäßendothels zeigt keinen zum Laufbandtraining zusätzlichen Effekt auf die 6-Minuten Gehstrecke

2018 ◽  
Vol 28 (01) ◽  
pp. 4-4
Author(s):  
K. Ammer
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Colony Stimulating Factor ◽  
Peripheral Artery ◽  
Supervised Exercise ◽  
Walking Performance ◽  
Macrophage Colony Stimulating Factor ◽  
Artery Disease ◽  
Macrophage Colony ◽  
Stimulating Factor

Referat zur Arbeit von McDermott MM, Ferrucci L, Tian L, Guralnik JM, Lloyd-Jones D, Kibbe MR, Polonsky TS, Domanchuk K, Stein JH, Zhao L, Taylor D, Skelly C, Pearce W, Perlman H, McCarthy W, Li L, Gao Y, Sufit R, Bloomfield CL, Criqui MH. Effect of Granulocyte-Macrophage Colony-Stimulating Factor With or Without Supervised Exercise on Walking Performance in Patients With Peripheral Artery Disease. The PROPEL Randomized Clinical Trial JAMA 2017; 318(21): 2089–2098

Sign in / Sign up

Export Citation Format

Share Document